Search the Newsreel

Novo Nordisk (CPSE:NOVO B) Sues Eli Lilly Over GLP 1 Drug Advertising

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) has filed a federal lawsuit against Eli Lilly over alleged false and misleading advertising of GLP-1 obesity and diabetes drugs. The company argues …

Is Novo Nordisk (CPSE:NOVO B) Fully Valued On EU Approval For Its Wegovy Pill?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) is back in focus after the European Commission granted marketing authorisation for its once daily Wegovy pill across all EU member …

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab. Continue Reading

Market Chatter: Novo Nordisk Seeks Immediate Court Order Against Lilly's Weight-Loss Drug Ads

(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.) Novo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Lilly Targets Early 2027 Filing for Next Obesity Drug

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) fell 0.35% in premarket after reporting positive results from two further Phase 3 trials of retatrutide and confirming it will submit a biologics license application to the FDA in the first quarter of 2027. The …

How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story

In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly's nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo's Wegovy and Ozempic. The case …

Why Novo Resources Corp stock plummeted yesterday

Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications

MCLEAN, Va., July 23, 2026--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer …

Envoy Medical (COCH) Projected to Release Quarterly Earnings on Thursday

Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

In the latest close session, Novo Nordisk (NVO) was down 2.41% at $48.19. This move lagged the S&P 500's daily loss of 0.14%. Elsewhere, the Dow saw a downswing of 0.01%, while the tech-heavy Nasdaq depreciated by 0.57%. The drugmaker's shares have seen an …

Filing of Leven Star Reef Technical Report

PERTH, Australia, July 22, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) reports that it has filed a technical report on the Company’s profile on the System for Electronic Data Analysis and Retrieval+ (SEDAR+) prepared …

EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant

Envoy Medical has reached a significant milestone, surpassing the three-month mark for all 56 patients in its pivotal clinical trial for the Acclaim cochlear implant. The company is on track for FDA submission and anticipates achieving six-month and twelve-month visit milestones by late 2026 …

FinVolution Group (FINV) Edges Lower, Hovering Near Key Support at $4.52 - Elliott Wave Entry

NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now

Novo Nordisk NVO has filed a lawsuit against Eli Lilly LLY, accusing its rival of misleading high-profile U.S. advertising campaigns to promote its blockbuster injectable GLP-1 medicines, Zepbound and Mounjaro, over NVO's injectable semaglutide medicines, Wegovy and Ozempic for obesity and type II diabetes …

Novo Nordisk (CPSE:NOVO B) Stock Looks Reasonable On Earnings While Returns Stay Weak

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk stock has had a tough stretch over the past few years, yet current valuation checks suggest the market may now be pricing it …

Novo sues Lilly, claiming misleading ads in weight-loss drug battle

View Comments

Update: Novo Nordisk Sues Eli Lilly Over Zepbound, Mounjaro Advertising

(Updates with Eli Lilly's response in the fifth and sixth paragraphs.) Novo Nordisk (NVO) said Tu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Novo Sues Lilly Over Weight-Loss Ad Claims

This article first appeared on GuruFocus. Novo Nordisk (NOVO_B) filed a lawsuit accusing Eli Lilly (NYSE:LLY) of running a "deliberately false" advertising campaign about the comparative effectiveness of their competing obesity and diabetes drugs. Novo Nordisk alleges Lilly cited outdated clinical trial data to …

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

Novo Nordisk NVO and Eli Lilly LLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk markets semaglutide as Ozempic and …

Weight-loss wars: Why Novo Nordisk is suing Eli Lilly

Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne. Video Transcript 00:00 Speaker A Novo Nordisk is filing …

Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled. Continue Reading

All 56 patients reach 3 months in Envoy Medical's hearing implant trial

Envoy Medical (NASDAQ: COCH) announced that all 56 patients in its pivotal clinical trial for the investigational Acclaim cochlear implant have completed their three-month visit milestone. This achievement is a crucial step toward the company's planned Premarket Approval (PMA) submission to the U.S. FDA. …

Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

Envoy Medical Inc. announced that all 56 patients in its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant have surpassed the three-month visit milestone. This achievement brings the company closer to submitting its Premarket Approval application to the FDA for the …

Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have …

Pharma heavyweights clash over anti-obesity drug ads

Anti-obesity treatments have been a financial windfall for Novo Nordisk and Eli Lily (SEBASTIEN BOZON) Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes treatments. …

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and …

Novo Nordisk Ramps Up DKK 15 Billion Share Buyback Programme

Novo Nordisk has initiated a share repurchase program targeting up to DKK 15 billion in buybacks over 12 months, starting February 4, 2026. The company had repurchased nearly 25 million B shares by July 17, 2026, holding 0.9% of its share capital as treasury …

Aspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry

South Africa's Aspen Pharmacare has received Canadian regulatory approval for Aspen-Semaglutide, a generic version of Novo Nordisk's Ozempic, for type 2 diabetes management. The launch timing in Canada depends on the availability of semaglutide API from India's Dr. Reddy's Laboratories, which has faced supply …

Novo Nordisk (CPSE:NOVO B) Launches Kyinsu In China Through Fangzhou Internet Hospital

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Novo Nordisk (CPSE:NOVO B) and Fangzhou have launched Kyinsu®, the world's first once weekly basal insulin/GLP-1 RA combination therapy, in China. The product is being introduced through …

Does EU Approval of Wegovy Pill Change NVO's Competitive Story?

Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity. The approval expands the company's obesity franchise across Europe, making Wegovy …

Citi lifts Novo Nordisk target on strong GLP-1 pill launch

Citi has raised its price target for Novo Nordisk (NYSE:NVO) to DKK330, citing strong launch performance of its GLP-1 pill, Wegovy. The broker increased sales and operating income estimates for 2026-2030 and expects the company to raise its full-year guidance, despite competition from Eli …

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 2026 CHMP meeting commences today, prior to FDA inspection classification for Catalent Indiana LLC (part of Novo Nordisk) fill-finish facility Apitegromab CHMP Opinion expected following resolution of Catalent Indiana classification status or inclusion of second fill-finish facility in MAA CAMBRIDGE, Mass., July 20, …

Novo Nordisk launches cheaper Ozempic in South Africa

Novo Nordisk has introduced a lower-cost version of its weight-loss drug, Ozempic, in South Africa, aiming to combat counterfeit products. This move follows a court victory against local pharmacies making unauthorized copies. South Africa has the highest adult obesity rate in Africa, and the …

FINV Q1 2026 Earnings: Strong EPS Performance Amid Market Uncertainty - Earnings Revision Report

Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

Fangzhou Inc. SHANGHAI, July 20, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced the launch of Kyinsu®, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, on its Internet hospital platform, …